UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                 For the quarterly period ended August 31, 2014

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

         For the transition period from ______________ to ______________

                         Commission File No. 333-168337


                                GroGenesis, Inc.
        (Exact Name of Small Business Issuer as specified in its charter)

           Nevada                                                42-1771870
(State or other jurisdiction of                               (I.R.S. employer
 incorporation or organization)                              identification no.)

                     Highway 79 North, Springville, TN 38256
                    (Address of principal executive offices)

        Registrant's telephone number, including area code: 855-691-4764

Check whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T during the
preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer [ ]                        Accelerated filer [ ]
Non-accelerated filer [ ]                          Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

81,490,000 shares of registrant's common stock, $0.001 par value, were
outstanding at October 20, 2014. Registrant has no other class of common equity.

                          PART I. FINANCIAL INFORMATION

ITEM 1 FINANCIAL STATEMENTS

GroGenesis, Inc.
August 31, 2014

                                                                          Index
                                                                          -----

Balance Sheets............................................................  3

Statements of Operations..................................................  4

Statements of Cash Flows..................................................  5

Notes to the Financial Statements.........................................  6

                                       2

GroGenesis, Inc.
Balance Sheets
(Expressed in US Dollars)



                                                                             August 31,              May 31,
                                                                               2014                   2013
                                                                           ------------           ------------
                                                                            (Unaudited)
                                                                                            
ASSETS

Current Assets
  Cash                                                                     $        317           $     12,188
  Prepaid expense                                                                16,800                 18,900
  Amounts receivable                                                              2,300                 19,000
  Inventory                                                                       6,374                  5,407
                                                                           ------------           ------------
Total Current Assets                                                             25,791                 55,495

Property, plant and equipment                                                   150,520                159,259
Intangible assets                                                               241,260                241,260
                                                                           ------------           ------------

Total Assets                                                               $    417,571           $    456,014
                                                                           ============           ============

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities
  Accounts payable and accrued liabilities                                 $    118,331           $    115,005
  Related party payables                                                         76,031                 36,103
  Advance                                                                        21,750                 21,750
                                                                           ------------           ------------

Total Liabilities                                                               216,112                172,858
                                                                           ------------           ------------
Stockholders' Deficit
  Common stock, 200,000,000 shares authorized, $0.001 par value;
   81,490,000 shares and 81,430,000 shares issued and outstanding
   as of August 31, 2014 and May 31, 2014, respectively                          81,490                 81,430
  Common stock subscribed                                                            --                 21,000
  Additional paid-in capital (deficiency)                                     1,626,540              1,605,600
  Deficit                                                                    (1,506,571)            (1,424,874)
                                                                           ------------           ------------
Total Stockholders' Equity (Deficit)                                            201,459                283,156
                                                                           ------------           ------------

Total Liabilities and Stockholders' Equity (Deficit)                       $    417,571           $    456,014
                                                                           ============           ============



   (The accompanying notes are an integral part of these financial statements)

                                       3

GroGenesis, Inc.
Statements of Operations
(Expressed in US Dollars)
(Unaudited)



                                                   For the                For the
                                                Three Months           Three Months
                                                   Ended                  Ended
                                                 August 31,             August 31,
                                                    2014                   2013
                                                ------------           ------------
                                                                 
Revenue                                         $     29,562           $         --
Cost of Sales                                         (7,099)                    --
                                                ------------           ------------
Gross Profit                                          22,463                     --
                                                ------------           ------------
Expenses
  Commissions                                          3,925                     --
  Consulting fees                                     37,500                     --
  Depreciation                                         8,739                     --
  General and administrative                          25,672                    968
  Transfer agent and filing fees                      13,231                     --
  Professional fees                                   15,093                  4,000
                                                ------------           ------------
Total Expenses                                      (104,160)                (4,968)
                                                ------------           ------------

Net Loss                                        $    (81,697)          $     (4,968)
                                                ============           ============

Net Loss Per Share - Basic and Diluted          $      (0.00)          $      (0.00)
                                                ============           ============

Weighted Average Shares Outstanding               81,483,000            135,000,000
                                                ============           ============



   (The accompanying notes are an integral part of these financial statements)

                                       4

GroGenesis, Inc.
Statements of Cash Flows
(Expressed in US Dollars)
(Unaudited)



                                                         For the            For the
                                                      Three Months       Three Months
                                                         Ended              Ended
                                                       August 31,         August 31,
                                                          2014               2013
                                                        --------           --------
                                                                     
Cash Flows Used in Operating Activities
  Net loss                                              $(81,697)          $ (4,968)
  Adjustments to reconcile to net cash
   used in operating activities:
     Depreciation                                          8,739                 --

  Changes in operating assets and liabilities:
    Prepaid expenses                                       2,100                 --
    Amounts receivable                                    16,700                 --
    Inventory                                               (967)                --
    Accounts payable and accrued liabilities               3,326                 --
    Related party payables                                39,928                 --
                                                        --------           --------
Net Cash Used In Operating Activities                    (11,871)            (4,968)
                                                        --------           --------
Cash Flows from Financing Activities
  Proceeds from common stock issued for cash              21,000                 --
  Proceeds from share subscriptions                      (21,000)                --
  Repayment of advances to related parties                    --             (4,450)
                                                        --------           --------
Net Cash Provided by Financing Activities                     --             (4,450)
                                                        --------           --------

(Decrease) in Cash                                       (11,871)            (9,418)

Cash - Beginning of Year                                  12,188              9,473
                                                        --------           --------

Cash - End of Year                                      $    317           $     55
                                                        ========           ========
Supplementary Information:
  Interest paid                                         $     --           $     --
                                                        ========           ========
  Income taxes paid                                     $     --           $     --
                                                        ========           ========



   (The accompanying notes are an integral part of these financial statements)

                                       5

GroGenesis, Inc.
Notes to the Financial Statements
August 31, 2014
(Unaudited)

Note 1: Nature and Continuance of Operations

GroGenesis, Inc. (the "Company") was incorporated in the state of Nevada on May
19, 2010. The Company was formed to become an operator of a beach shack in the
State of Goa, India.

On September 9, 2013, the Company entered into two asset purchase agreements
whereby the Company agreed to purchase certain assets necessary for the
operation of a plant growth surfactant manufacture and sales business. The
agreements closed on February 7, 2014. The assets acquired are used in
conjunction with the production, marketing, and sale of the crop surfactant to
be sold under the name "GroGenesis". Effective November 1, 2013, the Company
changed its name to GroGenesis, Inc. The Company's former president, Maria
Fernandes, resigned on closing. In addition, the Company has entered into an
easement agreement whereby it was granted the right to use a portion of a farm
located in Aylmer, Ontario, Canada for the purposes of using it as a
demonstration farm in order to evaluate and exhibit the effects of GroGenesis.

Note 2: Basis of Presentation

Unaudited Interim financial statements

The accompanying unaudited interim financial statements have been prepared in
accordance with United States generally accepted accounting principles for
interim financial information and with the instructions to Form 10-Q of
Regulation S-X. They may not include all information and footnotes required by
United States generally accepted accounting principles for complete financial
statements. However, except as disclosed herein, there has been no material
changes in the information disclosed in the notes to the financial statements
for the period ended May 31, 2014 included in the Company's Annual Report on
Form 10-K filed with the Securities and Exchange Commission on October 7, 2013.
These interim unaudited financial statements should be read in conjunction with
those financial statements included in the Annual Report Form 10-K. In the
opinion of management, all adjustments considered necessary for a fair
presentation, consisting solely of normal recurring adjustments, have been made.
Operating results for the three months ended August 31, 2014 are not necessarily
indicative of the results that may be expected for the year ending May 31, 2015.

Note 3: Going Concern

These financial statements have been prepared on a going concern basis which
assumes the Company will be able to realize its assets and discharge its
liabilities in the normal course of business for the foreseeable future. The
Company has incurred a loss since inception resulting in an accumulated deficit
of $1,506,571 as at August 31, 2014 and further losses are anticipated in the
development of its business raising substantial doubt about the Company's
ability to continue as a going concern. The ability to continue as a going
concern is dependent upon the Company generating profitable operations in the
future and/or obtaining the necessary financing to meet its obligations and
repay its liabilities arising from normal business operations when they come
due. Management intends to finance operating costs over the next twelve months
with existing cash on hand and loans from directors and/or the private placement
of common stock. There is however no assurance that the Company will be able to
raise any additional capital through any type of offering on terms acceptable to
the Company.

Note 4: Property and Equipment

                                                 Trade show       Manufacturing
                                                    booth           facility
                                                  --------          --------
                                                     $                 $
Cost:

Balance, May 31, 2014                               45,000           124,529
  Additions                                             --                --
                                                  --------          --------
Balance, August 31, 2014                            45,000           124,529
                                                  ========          ========
Accumulated amortization:

Balance, May 31, 2014                                6,611             3,659
  Additions                                          5,625             3,114
                                                  --------          --------
Balance, August 31, 2014                            12,236             6,773
                                                  ========          ========
Carrying amounts:

Balance, May 31, 2014                               38,389           120,870
                                                  --------          --------
Balance, August 31, 2014                            32,764           117,756
                                                  ========          ========

                                       6

Note 5: Intangible Assets

On September 30, 2014, the Company entered into an asset purchase agreement
(Note 9) whereby the Company issued 12,500,000 shares of restricted common stock
in exchange for intellectual property and related assets necessary for operating
a Plant Surfactant manufacture and sale business. The fair value of the
12,500,000 shares of common stock of $1,342,101 has been recorded as intangible
assets. On May 31, 2014, the Company performed an impairment test on the
intellectual property. The Company recorded impairment of $1,107,101, leaving a
carrying balance of $235,000 as at May 31, 2014.

The following represents changes in gross carrying amount of intangibles as at
August 31, 2014 and May 31, 2014:



                                                                                   Intellectual
                                             Trademark            Patent             Property
                                            ----------          ----------          ----------
                                                $                   $                   $
                                                                       
Cost:

Balance, May 31, 2014                            1,131               5,130           1,342,101
  Additions                                         --                  --                  --
                                            ----------          ----------          ----------
Balance, August 31, 2014                         1,131               5,130           1,342,101
                                            ==========          ==========          ==========
Accumulated amortization and impairment:

Balance, May 31, 2014                               --                  --           1,107,101
  Additions                                         --                  --                  --
  Impairment                                        --                  --                  --
                                            ----------          ----------          ----------
Balance, August 31, 2014                            --                  --           1,107,101
                                            ==========          ==========          ==========
Carrying amounts:

Balance, May 31, 2014                            1,131               5,130             235,000
                                            ----------          ----------          ----------
Balance, August 31, 2014                         1,131               5,130             235,000
                                            ==========          ==========          ==========


Note 6: Advance

As at August 31, 2014 the Company owed $21,750 to an associate of the Company's
management. The advance is unsecured, payable on demand and non-interest
bearing.

Note 7: Related Parties

On March 1, 2014, the Company entered into a Consulting Agreement with the
Company's Chief Operations Officer (the "COO") whereby the Company agreed to pay
the COO $2,500 per month. During the three months ended August 31, 2014, the
Company recorded $7,500 of consulting fees for services provided by the COO. As
at August 31, 2014, the Company owes the COO of the Company $15,000 (May 31,
2014 - $7,500), which is unsecured, non-interest bearing and due on demand.

On June 1, 2014, the Company entered into a Consulting Agreement with the
Company's Chief Financial Officer (the "CFO") whereby the Company agreed to pay
the CFO $2,500 per month. During the three months ended August 31, 2014, the
Company recorded $7,500 of consulting fees for services provided by the CFO. As
at August 31, 2014, the Company owes the CFO of the Company $7,500 (May 31, 2014
- $nil), which is unsecured, non-interest bearing and due on demand.

During the three months ended August 31, 2014, the Vice President of Sales and
Manufacturing ("VPSM") paid for expenses on behalf of the Company and collected
revenue on sales on behalf of the Company. As at August 31, 2014, the Company
owes the VPSM of the Company $26,217 (May 31, 2014 - $12,605), which is
unsecured, non-interest bearing and due on demand.

As at August 31, 2014, the Company owes the President of the Company $15,998
(May 31, 2014 - $15,998) for general and administration expenses and travel
expenses paid on behalf of the Company. The amount is unsecured, non-interest
bearing and due on demand.

The Company's manufacturing facility was leased under a 1-year rental agreement
at the rate of $800 per month, which lease term expired on May 22, 2014. The
lease continues on a month-to-month basis thereafter until terminated by either
party on written notice.

                                       7

During the period ended August 31, 2014, the Company received loans of $11,316
from two shareholders. These amounts are unsecured, non-interest bearing and
have no fixed terms of repayment.

Note 8: Capital Stock

Effective November 1, 2013, the number of common shares authorized that may be
issued by the Company increased from 75,000,000 common shares to 200,000,000
common shares with a par value of $0.001 per share.

The Company became a reporting company on June 27, 2012 and on August 21, 2012,
the Company completed the sale of 40,000,000 common shares at the price of
$0.0008 per share for total proceeds of $32,000.

Effective November 1, 2013, the Company completed a 25:1 forward split of the
Company's issued and outstanding common stock. Every one share of common stock
issued and outstanding prior to the split was exchanged for 25 post-split shares
of common stock. All share and per share amounts have been restated
retroactively.

On June 30, 2014, the Company completed a private placement consisting of 60,000
shares of common stock at a price of $0.35 per share for total proceeds of
$21,000, which was received prior to May 31, 2014.

As at August 31, 2014, the Company had 81,490,000 shares of common stock issued
and outstanding.

Note 9: Commitments

On September 9, 2013, the Company entered into an Asset Purchase Agreement
whereby the Company agreed to acquire intellectual property as well as all
related assets necessary for operating a plant growth enhancement product
("Plant Surfactant") manufacture and sale business. The agreement was closed on
February 7, 2014. In consideration, the Company issued 12,500,000 shares of
restricted common stock. In addition, the Company also agreed to incorporate a
wholly-owned subsidiary that will hold these assets and conduct operations, and
execute a consulting agreement with the President of the Company whereby he will
receive $7,000 per month. The consulting agreement will become effective on the
date that the Company raises a minimum of $500,000 to fund operations. As at
August 31, 2014, the Company had not incorporated a wholly-owned subsidiary.

On September 9, 2013, the Company entered into an Asset Purchase Agreement
whereby the Company agreed to acquire certain equipment used in conjunction with
the production, marketing and sale of the Plant Surfactant. The agreement was
closed on February 7, 2014. In consideration, the Company issued 5,000,000
shares of restricted common stock. In addition, the Company also agreed to
execute a consulting agreement with the seller whereby he will receive $5,000
per month. The consulting agreement will become effective on the date that the
Company raises a minimum of $500,000 to fund operations.

On September 9, 2013, the Company entered into an Easement Agreement whereby the
Company agreed to acquire the exclusive right to 10 acres of farm property
located in Aylmer, Ontario, Canada, to operate as a demonstration farm in order
to evaluate and exhibit the effects of using the Plant Surfactant for an initial
term of 3 years. In consideration, the Company issued 2,500,000 shares of
restricted common stock.

On March 1, 2014, the Company entered into a Consulting Agreement with the
Company's Chief Operations Officer (the "COO") whereby the Company agreed to pay
the COO $2,500 per month.

On March 1, 2014, the Company entered into a Consulting Agreement whereby the
Company agreed to pay the consultant $2,500 per month effective January 1, 2014.

On June 1, 2014, the Company entered into a Consulting Agreement with the
Company's Chief Financial Officer (the "CFO") whereby the Company agreed to pay
the CFO $2,500 per month.

                                       8

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS
        OF OPERATIONS

The following discussion of our financial condition, changes in financial
condition, plan of operations and results of operations should be read in
conjunction with our unaudited interim financial statements from the period
ended August 31, 2014, together with the notes thereto included in this Form
10-Q. The discussion contains forward-looking statements that involve risks,
uncertainties and assumptions. Our actual results may differ materially from
those anticipated in these forward-looking statements as a result of many
factors.

OVERVIEW

We are an operating company in the agricultural and environmental sectors
through our ownership, manufacture, and sale of a natural blend of plant
extracts that is used as a liquid plant growth enhancer, known as Agraburst crop
surfactant formula SURF0107 ("Agraburst"). A plant surfactant is a compound that
lowers the surface tension between a liquid and a solid in order to allow for
more efficient nutrient uptake in the plant. We commenced business in this
sector in February 2014.

Agraburst is designed to work as a cation exchange stimulant that penetrates
plant foliage and roots in order to enhance photosynthesis and higher brix
levels. The brix level is the percentage of solids, particularly sugar and
minerals, present in the plant. A high brix level is an indication that the
plant has been grown with sufficient nutrients and water. Minute particles in
Agraburst increase the speed of nutrient transport within a plant and can carry
other blended products into plant leaves.

The small particles within Agraburst have very close to a neutral electrical
charge, which allows them to form light bonds with the hydrogen atoms in water,
which results in a reduction in water's natural surface tension. As a result,
Agraburst acts akin to a lubricant that keeps water flowing and transporting
nutrients within a plant with little resistance. This promotes higher efficiency
of water and nutrient uptake in a plant. The resulting higher brix level in the
plant better enables it to resist disease, insects, drought, and cold weather.
It is also linked to better tasting food crops.

To date, Agraburst and predecessor product formulations have been sold to a
small group of farming clients and tested in a variety of case studies that has
resulted, amongst other benefits, in increased yield for corn, soybean, tobacco,
canola, alfalfa, wheat, cabbage, cotton, corn silage, hay, tomatoes, and beans.

PLAN OF OPERATION

Our plan of operation for the twelve month period following the date of this
report is to establish facilities for the commercial manufacture of Agraburst,
enter into distribution arrangements for the sale of Agraburst, and retain a
sales force necessary for the direct marketing of Agraburst to commercial
farmers in the United States and Canada.

We expect to incur the following costs in the next 12 months in connection with
our goals:

Manufacturing facilities and equipment costs:                $  500,000
Sales and Marketing:                                         $  350,000
Product manufacturing costs:                                 $  250,000
Consulting and distribution costs:                           $  200,000
Wages for sales force:                                       $  150,000
General and administrative costs:                            $   50,000
                                                             ----------
Total:                                                       $1,500,000
                                                             ==========

Total expenditures over the next 12 months are therefore expected to be
approximately $1,500,000. Our ability to meet these objectives will be dependent
on our ability to generate revenue from operations and to raise sufficient
additional capital to expand operations. If we are unable to generate sufficient
revenue or raise financing as required, we will delay our establishment and
expansion of operations as necessary.

                                       9

RESULTS OF OPERATIONS

We earned $29,562 in revenue during the three months ended August 31, 2014. Our
cost of sales for the period was $7,099 resulting in gross profit from
operations of $22,463.

For the three months ended August 31, 2014, we incurred total operating expenses
in the amount of $104,160, which consisted of consulting fees of $37,500,
general and administration fees of $25,672, professional fees of $15,093,
transfer agent and filing fees, of $13,231, depreciation expense of $8,739, and
commissions of $3,925. This resulted in a net loss of $81,697 for the period.

We have not incurred any expenses for research and development since inception.
As a result of operating losses, there has been no provision for the payment of
income taxes from the date of inception.

LIQUIDITY AND CAPITAL RESOURCES

As at August 31, 2014, we had a cash balance of $317 and total current assets of
$25,791.

As additional funds become required, we anticipate that this will come from
either advances from director or shareholder loans, or equity financing from the
sale of our common stock. If we are successful in completing an equity
financing, existing shareholders will experience dilution of their interest in
our company.

Our future financial results are also uncertain due to a number of factors, some
of which are outside our control. These factors include, but are not limited to:

o    our ability to raise additional funding;
o our ability to commercially develop the Agriburst intellectual property; and o
being able to generate sufficient sales of Agriburst in order to realize a
profit.

Due to our lack of operating history and present inability to generate revenues,
our auditors have stated their opinion that there currently exists a substantial
doubt about our ability to continue as a going concern.

GOING CONCERN CONSIDERATION

The report of our independent registered public accounting firm for the period
ended May 31, 2014 raises substantial doubt about our ability to continue as a
going concern based on the absence of an established source of revenue,
recurring losses from operations, and our need for additional financing in order
to fund our operations in fiscal 2014. Our operations and financial results are
subject to various risks and uncertainties that could adversely affect our
business, financial condition and results of operations.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements including arrangements that would
affect our liquidity, capital resources, market risk support and credit risk
support or other benefits.

FORWARD LOOKING STATEMENTS

The information in this quarterly report contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"). These forward-looking statements involve risks and uncertainties,
including statements regarding the Company's capital needs, business strategy
and expectations. Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "intend," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," the negative of such terms or
other comparable terminology. Actual events or results may differ materially. In
evaluating these statements, you should consider various factors, including the
risks outlined from time to time, in other reports we file with the Securities
and Exchange Commission (the "SEC"). These factors may cause our actual results
to differ materially from any forward-looking statement. We disclaim any
obligation to publicly update these statements, or disclose any difference
between its actual results and those reflected in these statements. The
information constitutes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995.

                                       10

ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURE ABOUT MARKET RISKS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities
Exchange Act of 1934 and are not required to provide the information under this
item.

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Based on our evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that our internal controls over financial reporting were not effective
as of August 31, 2014 and were subject to material weaknesses.

A material weakness is a deficiency, or a combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of the company's annual or interim
financial statements will not be prevented or detected on a timely basis. We
have identified the following material weaknesses in our internal control over
financial reporting using the criteria established in the COSO:

     1.   Failing to have an audit committee or other independent committee that
          is independent of management to assess internal control over financial
          reporting; and

     2.   Failing to have a director that qualifies as an audit committee
          financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K.

Because of its inherent limitations, internal control over financial reporting
may not prevent or detect misstatements. In addition, projections of any
evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions and that the
degree of compliance with the policies or procedures may deteriorate.

This annual report does not include an attestation report of our independent
registered public accounting firm regarding internal control over financial
reporting. Our internal control over financial reporting was not subject to
attestation by our independent registered public accounting firm pursuant to
temporary rules of the SEC that permit us to provide only management's report in
this annual report.

CONTROLS AND PROCEDURES OVER FINANCIAL REPORTING

Additionally, there were no changes in our internal controls over financial
reporting or in other factors that could significantly affect these controls
subsequent to the evaluation date. We have not identified any significant
deficiencies or material weaknesses in our internal controls, and therefore
there were no corrective actions taken.

                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company currently is not a party to any legal proceedings and, to the
Company's knowledge; no such proceedings are threatened or contemplated.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities
Exchange Act of 1934 and are not required to provide the information under this
item.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

                                       11

ITEM 3. DEFAULT UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

a. Exhibits

Exhibit
Number                        Description of Exhibit
------                        ----------------------
31.1     Certification of Principal Executive Officer pursuant to 18
         U.S.C.ss.1350, as adopted pursuant toss.302 of the Sarbanes-Oxley Act
         of 2002.

31.2     Certification of Principal Financial Officer pursuant to 18 U.S.C.ss.
         1350, as adopted pursuant to ss. 302 of the Sarbanes-Oxley Act of 2002.

32.1     Certification of Principal Executive Officer pursuant to 18
         U.S.C.ss.1350, as adopted pursuant toss.906 of the Sarbanes-Oxley Act
         of 2002.

32.2     Certification of Principal Financial Officer pursuant to 18 U.S.C. ss.
         1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002.

101      Interactive data files pursuant to Rule 405 of Regulation S-T.

                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereto duly
authorized.

Date: October 20, 2014

GROGENESIS, INC.


By: /s/ Joseph Fewer
   ---------------------------------
   Joseph Fewer
   Principal Executive Officer


By: /s/ Ron Evinou
   ---------------------------------
   Ron Evinou
   Principal Financial Officer

                                       12